People and Business News — 11/22
People News
physIQ announced Jason Luke has been appointed to the company’s Medical Advisory Board.
Canary Medical announced the appointment of Lisa Suennen as President, Digital and Data Solutions.
Business News
Emmes has expanded capabilities in India during the last two years and has seen surging growth in the region, with local revenue increasing by 400% and global study revenue increasing by more than 50%.
ACTO has been recognized as a Trailblazer in Life Sciences Commercial Analytics and Artificial Intelligence by Everest Group.
eClinical Solutions announced its accreditation in Medidata’s Site Cloud: End of Study platform.
The Almac Group has pledged to be net zero by 2045.
Quanticate announced plans for further expansion and new jobs in Toronto in 2023 as it thrives post-pandemic after it opened the office in 2019.
physIQ announced that OncoBay Clinical, Inc., has joined its Intrepid Partner Program.
Recognition
Elligo Health Research just won the Fast 50 Award, sponsored by the Austin Business Journal.
Jumo Health announced it has been recognized by Inc. Magazine in its inaugural Power Partner Awards.
AeroSafe Global announced that it earned the No. 1 spot on the 2022 Top 100 list of fast-growing, privately owned companies in the Rochester and Finger Lakes region.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
